8-K: INmune Bio Secures $9.7 Million in Registered Direct Offering

INmune Bio, a clinical-stage immunology company, has successfully raised approximately $9.7 million through a registered direct offering of common stock and warrants.

Summary

• INmune Bio, a clinical-stage immunology company, has entered into a securities purchase agreement to sell 986,000 shares of common stock and warrants to purchase an additional 986,000 shares.
• The offering was priced at $9.84 per share and accompanying warrant, resulting in gross proceeds of approximately $9.7 million before deducting fees and expenses.
• The warrants have an exercise price of $9.84 and terminate two years from the initial exercise date or 30 trading days after positive top-line data from the Phase 2 Alzheimer's program, whichever is earlier.
• Maxim Group LLC acted as the sole placement agent for the offering, receiving a 6% cash fee of the gross proceeds.
• The offering is expected to close around April 29, 2024, subject to customary closing conditions.
• The company intends to use the net proceeds to fund its ongoing Phase 2 trial in Early Alzheimer's Disease and its Phase 1 trial in metastatic castration-resistant prostate cancer.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company successfully raised capital, which is crucial for its operations. However, the use of warrants and the placement agent fee are slight negatives. The at-the-market pricing is a positive, indicating the company did not have to offer a significant discount to raise the funds.

Positives

• The company successfully raised a significant amount of capital to fund its clinical trials.
• The offering was priced at-the-market, which is generally seen as a positive for existing shareholders.
• The warrants include an acceleration clause that could lead to earlier exercise if the Alzheimer's trial is successful.
• The funds are earmarked for specific clinical trials, providing clarity on their use.

Negatives

• The offering includes warrants, which could dilute existing shareholders if exercised.
• The company will pay a 6% placement agent fee, which reduces the net proceeds from the offering.
• The warrants have a relatively short term of two years, which could put pressure on the company to achieve positive results in the Alzheimer's trial.

Risks

• The closing of the offering is subject to customary closing conditions, which could potentially delay or prevent the transaction.
• The company's clinical trials are in early stages, and there is no guarantee of success.
• The company may need to raise additional capital in the future if the current funding is insufficient.
• The warrants could dilute existing shareholders if exercised.

Future Outlook

The company expects the net proceeds to fund its ongoing Phase 2 trial in Early Alzheimer's Disease and its Phase 1 trial in metastatic castration-resistant prostate cancer.

Management Comments

• The press release states that the net proceeds is expected to fund the Company through the readout of the ongoing Phase 2 trial (AD02) in patients with Early Alzheimers Disease (AD) using XPro and through the metastatic castration-resistant prostate cancer (mCRPC) Phase 1 trial using the INKmune technology.

Industry Context

This capital raise is typical for clinical-stage biotech companies that need funding to advance their drug development programs. The focus on Alzheimer's and cancer treatments aligns with significant unmet medical needs and investor interest in these areas.

Comparison to Industry Standards

• The at-the-market pricing is a common method for biotech companies to raise capital without significant discounts.
• The use of warrants is also a typical feature in biotech financings, providing investors with potential upside.
• The 6% placement agent fee is within the typical range for such transactions.
• Comparable companies raising capital include those in the clinical-stage biotech space, such as those developing novel therapies for neurodegenerative diseases and cancer. For example, companies like Cassava Sciences (SAVA) and Amylyx Pharmaceuticals (AMLX) in the Alzheimer's space, and companies like Arcus Biosciences (RCUS) and Iovance Biotherapeutics (IOVA) in the cancer space, have all raised capital through similar methods.

Stakeholder Impact

• Shareholders may experience dilution if the warrants are exercised.
• The company's employees will benefit from the continued funding of the company's operations.
• Patients with Alzheimer's and prostate cancer may benefit from the development of new treatments.
• Creditors and suppliers will benefit from the company's improved financial position.

Next Steps

• The company will close the offering on or about April 29, 2024.
• The company will use the net proceeds to fund its ongoing Phase 2 Alzheimer's trial and Phase 1 prostate cancer trial.
• The company will continue to develop its drug candidates and report on clinical trial progress.

Key Dates

Keywords

registered direct offering, common stock, warrants, clinical-stage, immunology, Alzheimer's disease, prostate cancer, capital raise, Maxim Group LLC, XPro1595, INKmune